Navigation Links
Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007
Date:2/13/2008

ory authorities or commercially available in the time frame we anticipate, or at all, (vi) we may not be able to compete effectively, (vii) we may not be able to maintain our current corporate collaborations and enter into new corporate collaborations or customer contracts, (viii) we are dependent on Novartis, Siemens (as assignee of Bayer) and other third parties for the distribution of some of our products, (ix) we are dependent on a small number of customers, contract manufacturers and single source suppliers of raw materials, (x) changes in third-party reimbursement policies regarding our products could adversely affect sales of our products, (xi) changes in government regulation affecting our diagnostic products could harm our sales and increase our development costs, (xii) the risk that our intellectual property may be infringed by third parties or invalidated, and (xiii) our involvement in patent and other intellectual property and commercial litigation could be expensive and could divert management's attention. The foregoing list sets forth some, but not all, of the factors that could affect our ability to achieve results described in any forward-looking statements. For additional information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we file with the SEC, including our most recent annual report on Form 10-K and all subsequent periodic reports. We assume no obligation and expressly disclaim any duty to update forward-looking statements to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.

Gen-Probe Incorporated

Consolidated Balance Sheets

(In thousands, except share and per share data)

December 31, December 31,

2007 2006


'/>"/>
SOURCE Gen-Probe Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Carl Hull Named President and Chief Operating Officer of Gen-Probe
2. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call
3. Gen-Probe to Webcast Three Upcoming Presentations
4. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
5. Gen-Probe to Webcast Presentation at Bank of Americas 37th Annual Investment Conference
6. Imagenetix Inc. Reports Third Fiscal Quarter Results
7. China-Biotics, Inc. Reports Third Quarter 2008 Financial Results
8. Maxygen Reports Fourth Quarter and Year End 2007 Financial Results
9. Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007
10. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
11. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)...  Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary ... that Cassian Yee , M.D., Professor, Department of ... University of Texas MD Anderson Cancer Center joined its ... of Immunology, Division of Cancer Medicine, and Director, Solid ... the University of Texas MD Anderson Cancer Center.  ...
(Date:5/6/2015)... The Remedy Group , the ... the specialty pharmacy industry, will be exhibiting, presenting, and ... Pharmacy Summit. The Summit will be held May 4-8, ... is the largest annual gathering for the specialty pharmacy ... pharmacy providers, pharma/biotech manufacturers, and payers, to learn more ...
(Date:5/5/2015)... 5, 2015  23andMe, Inc., the leading personal genetics ... Research Study in collaboration with Pfizer Inc. The ... erythematosus, more commonly known as lupus, into the study ... effort is also in collaboration with the Lupus Research ... May. Approximately 1.5 million people in the ...
(Date:5/5/2015)... May 5, 2015  Tikcro Technologies Ltd. (OTCQB: ... to continue trading on OTCQB  Marketplace, the market ... Marketplace allows for a continuous public market for ... have real-time quotes and market information on us ... OTCQB Marketplace includes U.S. and international companies in ...
Breaking Biology Technology:Oxis Biotech Appoints Cassian Yee, M.D. To Its Scientific Advisory Board 2Oxis Biotech Appoints Cassian Yee, M.D. To Its Scientific Advisory Board 3The Remedy Group presenting at the 2015 Armada Specialty Pharmacy Summit: The Pitfalls to Growth and Maintaining the Patient Experience 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 3Tikcro Technologies Announces Approval to Continue Trading on OTCQB 2
... combines the simplicity of protein precipitation with ... removal of phospholipids and proteins from biological ... 8 Supelco, a division of Sigma-Aldrich ... leading supplier of chromatography products for analysis ...
... ImQuest Life Sciences presented their latest biological results ... molecule piperazine compound for the treatment of solid ... in Whistler, British Columbia. The presentation highlighted advances ... IQP-0304. The piperazines demonstrate potent antiproliferative activity against ...
... Upregulation by Percutaneous Administration of Gene Therapy in ... Effects of SERCA2a Enzyme Replacement Using Gene TransferSAN ... the publication of results from a Phase 1/2 ... replacement therapy for advanced heart failure, in the ...
Cached Biology Technology:HybridSPE(TM)-Precipitation Technology Wins SelectScience.net 2009 Scientists' Choice Award for Best New Separations Product in 2008 2HybridSPE(TM)-Precipitation Technology Wins SelectScience.net 2009 Scientists' Choice Award for Best New Separations Product in 2008 3ImQuest Presentation at Keystone Symposium Focuses on Advancements in Their Cancer Research and Development Program 2The Journal of Cardiac Failure Publishes Results From Celladon Corporation's First-in-Human Phase 1/2 Clinical Trial in Advanced Heart Failure 2The Journal of Cardiac Failure Publishes Results From Celladon Corporation's First-in-Human Phase 1/2 Clinical Trial in Advanced Heart Failure 3
(Date:4/13/2015)... April 13, 2015 According ... "Global Biometrics Market Forecast & Opportunities, 2020", the global ... of around 14% till 2020. The biometrics market ... scale implementation and review of biometric management systems. ... new products with greater efficiency, are resulting in ...
(Date:4/8/2015)... 8, 2015  Infinisource, a leading provider of SaaS-based ... Morpho, a leading supplier of biometric identification and ... market,s most advanced biometrically-enabled time clock, the companies ... clock is setting a bold, new standard for ... the small and mid-size employer. When connected to ...
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Revises Revenues for Q1 2015 2
... are small fat capsules, often added to beauty products. ... of transporting active ingredients deep into the skin and ... the skins structure by rejuvenating and smoothing the skin. ... shows that liposomes are not capable of transporting themselves ...
... are expected to attend an INSECT EXPO at New Mexico ... February 25 at the start of the 2013 Annual Meeting ... (ESA), which will be held February 25-28 in the Ramada ... free educational event will reinforce students, science skills with hands-on ...
... P. Sloan Foundation is pleased to announce the selection ... of Sloan Research Fellowships for 2013. , Awarded ... scientists and scholars whose achievements and potential identify them ... "The Sloan Research Fellows are the best of ...
Cached Biology News:Don't trust liposomes in your beauty products 2Sloan Foundation announces 2013 Sloan Research Fellows 2
Goat polyclonal to DDDDK tag (FITC) ( Abpromise for all tested applications)....
...
DNA fragmentation factor & Inhibitor of CAD...
Component in MasterPure™ Purification Kits...
Biology Products: